Table 2.
Results from Meta-regression Analyses
| Variable | Model 1 a | Model 2 b | ||
|---|---|---|---|---|
| Coefficient | P Value | Coefficient | P Value | |
| Intervention | ||||
| Reference: screening | ||||
| Noninvasive diagnostic | 0.00 (0.00) | 0.78 | — | — |
| Invasive diagnostic | –0.06 (0.06) | 0.30 | — | — |
| Surgery | –0.15 (0.03) | <0.001* | — | — |
| Radiation | –0.17 (0.04) | <0.001* | — | — |
| Surgery and radiation | –0.24 (0.04) | <0.001* | — | — |
| Chemotherapy | –0.19 (0.04) | <0.001* | — | — |
| Endocrine therapy | –0.12 (0.03) | <0.001* | — | — |
| Breast cancer stage | ||||
| Reference: early | ||||
| Advanced/metastatic | — | — | –0.11 (0.08) | 0.18 |
| Non-specific | — | — | –0.02 (0.08) | 0.76 |
| Study sample size | 0.00 (0.00) | 0.53 | 0.00 (0.00) | 0.82 |
| Valuation method | ||||
| Reference: EQ-5D | ||||
| SG | 0.09 (0.03) | <0.01* | 0.14 (0.08) | 0.09 |
| TTO | 0.06 (0.03) | 0.08 | 0.17 (0.06) | <0.05* |
| VAS | –0.04 (0.02) | <0.05* | –0.03 (0.08) | 0.69 |
| Other | –0.01 (0.06) | 0.84 | –0.01 (0.05) | 0.86 |
| Respondents | ||||
| Reference: Patients | ||||
| Public | –0.04 (0.03) | 0.13 | –0.26 (0.07) | < 0.01* |
| Constant | 0.92 (0.04) | < 0.001* | 0.80 (0.08) | < 0.001* |
By the intervention in model 1: observations: N of health utilities in the model = 88; R2 = 0.57. Studies included in model 1: reference number (number of utilities contributed by the study): 17(2), 21(6), 23(4), 24(14), 26(3), 27(3), 46(4), 48(3), 51(2), 52(1), 55(6), 56(3), 57(1), 60(2), 62(2), 63(1), 64(6), 70(4), 78(4), 79(1), 80(1), 84(3), 87(3), 89(1), 92(2), 94(1), 97(4).
By breast cancer stage in model 2: observations: N of health utilities in the model = 52; R2 = 0.37. Studies included in model 2: reference number (number of utilities contributed by the study): 9(2), 16(1),18(1),19(1), 24(8), 29(8), 30(3), 48(2), 49(1), 51(1), 53(3), 55(3), 57(1), 64(2), 68(1), 72(1),75(2), 82(1), 88(1), 91(1), 97(4), 99(1), 100(1), 101(2).
Significant P value.